Not enough younger black women referred for BRCA testing
Few black women aged 50 years or younger eligible for genetic testing for breast cancer had been referred for such testing or genetic counseling.
Few black women aged 50 years or younger eligible for genetic testing for breast cancer had been referred for such testing or genetic counseling.
A breast cancer risk model for African-American women underpredicted individual risk and risk of estrogen receptor (ER)-negative disease.
Delays between a breast cancer diagnosis and treatment increase the risk of death for women with late-stage cancers, according to a recently published study. A second study found that the median wait time between diagnosis and treatment has grown longer.
Black women have the highest death rate from breast cancer of all racial and ethnic groups, and are 40% more likely to die of the disease than are white women, according to a new report from the CDC.
Among patients with renal cell carcinoma, whites consistently have a survival advantage over blacks, regardless of patient or tumor characteristics or surgical treatment. These findings suggest the need for additional efforts to prolong the survival of all patients with kidney cancer.
Many persons who receive chemotherapy for incurable cancers may not understand that the treatment is unlikely to be curative.
Non-Hispanic black women with breast cancer, specifically estrogen-positive tumors, are at a significantly increased risk for breast cancer death compared with non-Hispanic white women. The difference is greatest in the first 3 years after diagnosis.
Racial disparities in the quality of communication between physicians and patients were further confirmed by a study comparing how physicians discuss clinical trials during clinical interactions with black patients versus white patients.
Among patients with colorectal cancer, 29% in a nationally representative sample were diagnosed after an emergency, such as an obstruction or perforation of the bowel.
The mailing of fecal occult blood test (FOBT) kits boosted colorectal cancer screening rates in a low-income, racially diverse patient population.